CSPCY (CSPC Pharmaceutical Group) Moat Score: 6/10 (As of Jul. 02, 2026)


CSPCY CSPC Pharmaceutical Group Ltd CSPCY
79 GF Score
Price $3.55
GF Value $3.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Moat Score?

CSPC Pharmaceutical Group CSPCY +1.18% 79 Moat Score is 6 as of Jul. 02, 2026. GuruFocus rates CSPCY with a GF Score™ of 79/100 and a GF Value™ of $3.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks better than 97.09% on this metric.

CSPC Pharmaceutical Group has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

CSPC Pharmaceutical Group has Narrow Moat: CSPC Pharmaceutical Group Ltd has a strong narrow moat with valuable intellectual property and consistent R&D capabilities. It benefits from economies of scale and some regulatory barriers, but lacks the extensive market dominance required for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CSPC Pharmaceutical Group might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

CSPC Pharmaceutical Group  (OTCPK:CSPCY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CSPC Pharmaceutical Group Moat Score Related Terms

CSPCY vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Moat Score distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Moat Score falls into.


CSPCY
79GF Score
CSPC Pharmaceutical Group Ltd CSPCY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
CSPC Pharmaceutical Group (CSPCY) has a Moat Score of 6 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #30 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is CSPC Pharmaceutical Group's Moat Score too high?
CSPC Pharmaceutical Group's current Moat Score is 6. Based on the distribution chart, CSPC Pharmaceutical Group ranks #30 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CSPC Pharmaceutical Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #30 out of 1031 companies for Moat Score. This places CSPC Pharmaceutical Group in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. CSPC Pharmaceutical Group's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Fairly Valued. The stock's GF Value™ is $3.31, compared to a current price of $3.55 — trading 7.3% above its estimated fair value. The current Moat Score is 6. CSPC Pharmaceutical Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Moat Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $3.55 is trading 7.3% above its estimated GF Value™ of $3.31. GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.

Key valuation signals for CSPCY:

  • Moat Score: 6
  • GF Value™: $3.31 vs. price of $3.55 (7.3% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
79GF Score

Get the complete analysis for CSPCY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$3.31
GF Value